Skip to main content

TAKEDA PHARMACEUTICAL COMPANY LIMITED

corporate_fare Company Profile

TAKEDA PHARMACEUTICAL COMPANY LIMITED

TAK·NYSE·Life Sciences·CIK 0001395064

Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company that researches, develops, produces, and commercializes biopharmaceutical products worldwide. The company aims to translate scientific discoveries into innovative, life-transforming medicines. Takeda's R&D efforts concentrate on three core therapeutic areas, utilizing both internal research and external partnerships to access various treatment methods, including biologics and small molecules. Takeda operates a geographically diversified global business, marketing its prescription drugs worldwide. The company has approximately 47,000 employees globally. Its commercial focus is on six key business areas: GI (Gastrointestinal), Rare Diseases, PDT (Plasma-Derived Therapies), Oncology, Vaccines, and Neuroscience. These six areas collectively generated 94.4% of Takeda's total revenue in the fiscal year ended March 31, 2025. The company's global head office is located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, 103-8668, Japan.

TAKEDA PHARMACEUTICAL COMPANY LIMITED (NYSE:TAK) is a publicly traded company in the Life Sciences sector. Wiseek monitors TAK SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Takeda Issues $539M in Shares for Employee Long-Term Incentive Plan
  • Takeda Finalizes $2.5B Antitrust Provision, Revising FY2025 Reported Net Profit to a Loss
  • Takeda Refiles Shelf Registration for JPY 240B Long-Term Incentive Plan, Expects 1.1% Dilution
  • Takeda Proposes Increased Dividend and Board Restructuring for Annual Shareholder Meeting
  • Takeda Reports $813M Impairment Losses & $445M Restructuring Costs in FY2026 Financial Notes

Financial Snapshot

Fiscal year ended March 31, 2025
Revenue
¥4.58T JPY
Net Income
¥108.14B JPY
Diluted EPS
¥67.23 JPY
Op. Cash Flow
¥1.06T JPY
Free Cash Flow
¥856.39B JPY
Gross Profit
¥3T JPY
Operating Income
¥342.59B JPY
Cash & Equivalents
¥233.74B JPY
Total Debt
¥3.97T JPY
Debt / Equity
0.57×
Net Margin
2.4%
Shares Outstanding
1.59B sh
Source: 20-F · filed 2025-06-25 · accession 0001395064-25-000095

Insider Transactions

TAK files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with T →
$15.91
52-week range · as of 2026-06-09 $12.99 – $18.89
Market cap
$50.35B
Volume
4M (1.2× avg)
3-mo avg 3.3M
Live data · 2026-06-14 06:09 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TAK - Latest Insights

TAK
Jun 09, 2026, 6:09 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $15.55
Real-time Price: $15.91 info
Change: +$0.360 (+2%) info
Market Cap: $50.352B info
TAK
Jun 05, 2026, 6:27 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $15.22
Real-time Price: $15.91 info
Change: +$0.690 (+5%) info
Market Cap: $50.352B info
TAK
Jun 01, 2026, 6:06 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $15.35
Real-time Price: $15.91 info
Change: +$0.560 (+4%) info
Market Cap: $50.352B info
TAK
May 26, 2026, 6:12 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $15.90
Real-time Price: $15.91 info
Change: +$0.0100 (+0.06%) info
Market Cap: $50.352B info
TAK
May 26, 2026, 6:11 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $15.90
Real-time Price: $15.91 info
Change: +$0.0100 (+0.06%) info
Market Cap: $50.352B info
TAK
May 26, 2026, 6:11 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $15.90
Real-time Price: $15.91 info
Change: +$0.0100 (+0.06%) info
Market Cap: $50.352B info
TAK
May 26, 2026, 6:10 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $15.90
Real-time Price: $15.91 info
Change: +$0.0100 (+0.06%) info
Market Cap: $50.352B info
TAK
May 26, 2026, 6:10 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $15.90
Real-time Price: $15.91 info
Change: +$0.0100 (+0.06%) info
Market Cap: $50.352B info
TAK
May 19, 2026, 6:10 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $16.57
Real-time Price: $15.91 info
Change: -$0.660 (-4%) info
Market Cap: $50.352B info
TAK
May 13, 2026, 6:03 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $16.45
Real-time Price: $15.91 info
Change: -$0.540 (-3%) info
Market Cap: $50.352B info
TAK
May 13, 2026, 2:38 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $16.35
Real-time Price: $15.91 info
Change: -$0.440 (-3%) info
Market Cap: $50.352B info
TAK
Mar 30, 2026, 6:27 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $18.09
Real-time Price: $15.91 info
Change: -$2.18 (-12%) info
Market Cap: $50.352B info
TAK
Mar 26, 2026, 6:03 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $18.29
Real-time Price: $15.91 info
Change: -$2.38 (-13%) info
Market Cap: $50.352B info
TAK
Mar 25, 2026, 6:03 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $18.03
Real-time Price: $15.91 info
Change: -$2.12 (-12%) info
Market Cap: $50.352B info
TAK
Mar 02, 2026, 6:04 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $18.75
Real-time Price: $15.91 info
Change: -$2.84 (-15%) info
Market Cap: $50.352B info
TAK
Feb 10, 2026, 6:01 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $17.98
Real-time Price: $15.91 info
Change: -$2.07 (-12%) info
Market Cap: $50.352B info
TAK
Jan 29, 2026, 6:02 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $16.78
Real-time Price: $15.91 info
Change: -$0.870 (-5%) info
Market Cap: $50.352B info